Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood (2008) 20.32

Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell (2014) 2.43

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol (2007) 1.48

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer (2010) 1.40

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood (2010) 1.34

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia (2009) 1.30

Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol (2010) 1.30

Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol (2010) 1.16

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol (2010) 1.13

Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag (2009) 1.12

Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag (2007) 1.05

Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene (2012) 0.99

Antibody therapy for chronic lymphocytic leukemia. Semin Hematol (2008) 0.95

Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer (2009) 0.93

Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol (2007) 0.91

Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood (2015) 0.89

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol (2014) 0.86

The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant (2013) 0.85

Management of chronic lymphocytic leukemia. Haematologica (2014) 0.85

Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies. Can Respir J (2008) 0.79

Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol (2012) 0.77

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther (2010) 0.77

Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev Anticancer Ther (2011) 0.76

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia. Blood Cancer J (2011) 0.75

Alemtuzumab in the up-front setting. Ther Clin Risk Manag (2008) 0.75

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL). Biologics (2008) 0.75

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leuk Lymphoma (2013) 0.75

Chronic lymphocytic leukemia: inception to cure: are we there? Indian J Hematol Blood Transfus (2012) 0.75

Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia (2003) 13.41

Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer (1997) 8.27

Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science (2001) 4.61

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 4.12

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet (1996) 3.75

Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46

Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg (1993) 3.45

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood (2009) 3.21

Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol (2000) 3.10

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91

ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr (2006) 2.89

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78

Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet (1993) 2.64

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood (1999) 2.56

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50

Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J (1990) 2.42

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2006) 2.38

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24

Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med (2000) 2.17

Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev (2004) 2.17

Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene (2007) 2.08

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol (2012) 2.03

Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection (2012) 2.02

Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer (1993) 2.01

Is codon 129 of prion protein polymorphic in human beings but not in animals? Lancet (1997) 1.99

Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98

DNMT3A mutations in myeloproliferative neoplasms. Leukemia (2011) 1.95

Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia (2009) 1.92

Crimean-Congo haemorrhagic fever in Oman. Lancet (1995) 1.90

Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem (1995) 1.86

Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene (1998) 1.81

Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg (1994) 1.75

Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72

High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72

Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia (2006) 1.70

Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. Blood (2000) 1.70

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol (2001) 1.70

B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet (2001) 1.70

Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg (1996) 1.69

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69

11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood (1997) 1.69

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol (2003) 1.66

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia (2007) 1.64

Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand (2006) 1.63

Social phobia in spasmodic torticollis. J Neurol Neurosurg Psychiatry (2001) 1.62

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia (2006) 1.62

Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol (2004) 1.62

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia (2012) 1.60

Stented versus nonstented pancreaticojejunostomy after pancreatoduodenectomy: a prospective study. Ann Surg (1999) 1.60

Formation of a highly peptide-receptive state of class II MHC. Immunity (1998) 1.58

Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood (1999) 1.55

Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity (2000) 1.54

High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol (1990) 1.54

A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol (2004) 1.54

Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis (2000) 1.53

High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum Gene Ther (1995) 1.52

[Comparison of the quality of life after subtotal and total gastrectomy for stomach carcinoma]. Dtsch Med Wochenschr (1996) 1.50

Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer (2001) 1.49

Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer (1998) 1.49

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.48

The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia (2006) 1.47

Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther (2001) 1.47

Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A (2000) 1.46

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia (2007) 1.43

Travel-related Toscana virus infection. Lancet (1993) 1.43

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.42

The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia (2007) 1.42

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer (2010) 1.42

Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer (1998) 1.42

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood (2001) 1.41

[Vaccination against rabies: how and when?]. Dtsch Med Wochenschr (2012) 1.41

Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography. Ultrasound Obstet Gynecol (1997) 1.41

APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39

Neonatal hemochromatosis: a rare cause of nonimmune hydrops fetalis and fetal anemia. Fetal Diagn Ther (1994) 1.39

Genomic imbalances are rare in hairy cell leukemia. Genes Chromosomes Cancer (1999) 1.39